A 64-year-old man with type 2 diabetes (10 years' duration), prior myocardial infarction and hypertension has an HbA1c of 59 mmol/mol (7.5%) on maximally tolerated metformin. eGFR is 55 mL/min/1.73 m² and urinary albumin-creatinine ratio is 8 mg/mmol. According to contemporary Australian guidance, which additional glucose-lowering agent is most appropriate to improve cardiovascular and renal outcomes?